Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Research & Development: 2018-2024

Historic Research & Development for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to $83.1 million.

  • Pharming Group N.V's Research & Development fell 11.76% to -$44.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $38.3 million, marking a year-over-year decrease of 18.16%. This contributed to the annual value of $83.1 million for FY2024, which is 20.65% up from last year.
  • Pharming Group N.V's Research & Development amounted to $83.1 million in FY2024, which was up 20.65% from $68.9 million recorded in FY2023.
  • Pharming Group N.V's Research & Development's 5-year high stood at $83.1 million during FY2024, with a 5-year trough of $38.5 million in FY2020.
  • Moreover, its 3-year median value for Research & Development was $68.9 million (2023), whereas its average is $68.2 million.
  • As far as peak fluctuations go, Pharming Group N.V's Research & Development spiked by 82.77% in 2021, and later decreased by 25.38% in 2022.
  • Yearly analysis of 5 years shows Pharming Group N.V's Research & Development stood at $38.5 million in 2020, then spiked by 82.77% to $70.4 million in 2021, then decreased by 25.38% to $52.5 million in 2022, then spiked by 31.19% to $68.9 million in 2023, then climbed by 20.65% to $83.1 million in 2024.